Methysergide contraindications: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Methysergide}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS P...")
 
mNo edit summary
 
Line 3: Line 3:
{{CMG}}
{{CMG}}


==
==Contraindications==


 
Hypersensitivity to the drug or to tartrazine (FD&C Yellow #5) or any other components of the formulation, pregnancy, lactation, peripheral vascular disease, severe arteriosclerosis, severe hypertension, coronary artery disease, phlebitis or cellulitis of the lower limbs, pulmonary disease, collagen diseases or fibrotic processes, impaired liver or renal function, valvular heart disease, debilitated states and serious infections.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fae28ee-700e-4d4f-a040-02ef01a2aeb4 | publisher =  | date =  | accessdate = }}</ref>
 
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3fae28ee-700e-4d4f-a040-02ef01a2aeb4 | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Latest revision as of 19:19, 7 February 2014

Methysergide
SANSERT® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Clinical Trials on Methysergide
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Contraindications

Hypersensitivity to the drug or to tartrazine (FD&C Yellow #5) or any other components of the formulation, pregnancy, lactation, peripheral vascular disease, severe arteriosclerosis, severe hypertension, coronary artery disease, phlebitis or cellulitis of the lower limbs, pulmonary disease, collagen diseases or fibrotic processes, impaired liver or renal function, valvular heart disease, debilitated states and serious infections.[1]

References

  1. "SANSERT (METHYSERGIDE MALEATE) TABLET, COATED [NOVARTIS PHARMACEUTICALS CORPORATION]".

Adapted from the FDA Package Insert.